Filtered By:
Specialty: Urology & Nephrology
Management: Medicare
This page shows you your search results in order of date.
Order by Relevance | Date
Total 460 results found since Jan 2013.
Association between urology practice use of multiparametric MRI and genomic testing and treatment of men with newly diagnosed prostate cancer
CONCLUSIONS: Compared to practices that do not use each biomarker in men with newly diagnosed prostate cancer, urology practices using mpMRI, and tissue-based genomics to a lesser extent, are more likely to treat men at very high risk of dying from competing risks of mortality within 10 years of prostate cancer diagnosis.PMID:37580226 | DOI:10.1016/j.urolonc.2023.08.002
Source: Urologic Oncology - August 14, 2023 Category: Urology & Nephrology Authors: Kassem S Faraj Samuel R Kaufman Lindsey A Herrel Mary K Oerline Avinash Maganty Vahakn B Shahinian Brent K Hollenbeck Source Type: research
Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006-2018: Effect of race, age and socioeconomic status on treatment disparities
CONCLUSION: In patients with a diagnosis of high risk NMIBC, disparities in utilization of BCG are seen based on SES, age, and insurance type.PMID:37295979 | DOI:10.1016/j.urolonc.2023.05.019
Source: Urologic Oncology - June 9, 2023 Category: Urology & Nephrology Authors: Onika Dv Noel Eric Stewart Rosemary Cress Marc A Dall'Era Anshu Shrestha Source Type: research
Patterns of multispecialty care for low- and intermediate-risk prostate cancer in the use of active surveillance
CONCLUSIONS: Uptake of AS among men with low-risk PC has occurred primarily under the purview of urologists. While selection is certainly at play, these data suggest that multispecialty care may not be required to promote the utilization of AS for men with low-risk PC.PMID:37286404 | DOI:10.1016/j.urolonc.2023.04.024
Source: Urologic Oncology - June 7, 2023 Category: Urology & Nephrology Authors: Ibardo A Zambrano Soohyun Hwang Ram Basak Brooke Namboodri Spratte Christopher P Filson Bruce L Jacobs Hung-Jui Tan Source Type: research
Insurer coverage of prostate cancer biomarkers
CONCLUSIONS: Coverage of novel CaP biomarkers are relatively robust for Medicare plans but sparse for non-Medicare plans, with the majority of non-Medicare plans requiring prior authorization. Non-Medicare eligible men may face significant barriers to obtaining these tests.PMID:37225635 | DOI:10.1016/j.urolonc.2023.04.020
Source: Urologic Oncology - May 24, 2023 Category: Urology & Nephrology Authors: Aaron Brant Ilon C Weinstein Patrick Lewicki Alec Zhu Jeffrey P Johnson Christina Sze Jonathan E Shoag Source Type: research
Use of expectant management based on prostate cancer risk and health status: How far are we from a risk-adapted approach?
CONCLUSIONS: EM increased significantly over time for patients with low- and favorable intermediate-risk disease, with the most notable differences based on age and Gleason score. In contrast, trends in uptake of EM did not differ substantively by health status, suggesting that physicians may not be effectively incorporating patient health into PCa treatment decisions. Additional work is needed to develop interventions that recognize health status as an essential component of a risk-adapted approach.PMID:37149430 | DOI:10.1016/j.urolonc.2023.04.006
Source: Urologic Oncology - May 6, 2023 Category: Urology & Nephrology Authors: Brooke Namboodri Spratte Hung-Jui Tan Ibardo A Zambrano Ram Sankar Basak Christopher P Filson Bruce L Jacobs Soohyun Hwang Source Type: research
Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis
CONCLUSIONS: The findings of this preliminary cost-effectiveness analysis are novel in that they highlight a well tolerated, efficacious drug that is less expensive than the traditional gold standard therapy. In modern medicine, we are more often challenged by agents with marginally increased efficacy but at significantly higher costs; gemcitabine-docetaxel represents a rare entity which is a success for both patients and healthcare systems alike.PMID:37127478 | DOI:10.1016/j.urolonc.2023.04.005
Source: Urologic Oncology - May 1, 2023 Category: Urology & Nephrology Authors: Laura Bukavina Spencer Bell Vignesh T Packiam Marc Smaldone Philip Abbosh Robert Uzzo Alexander Kutikov Andres F Correa Diana E Magee Source Type: research
